Vice President, Vaccines, Commercial Strategy, GlaxoSmithKline
Kimberly Sablich, vice president for vaccines commercial strategy at GlaxoSmithKline, ascended quickly in her pharma career,
and she credits it to growing up in a household with a single working mother. "With my mother as a role model, I never questioned
whether I was going to have a career and I was always sure I wanted to be in the business world, like Mom," says Sablich.
As a witness to the great healthcare debate of the Clinton era, Sablich was drawn into healthcare and ultimately pharmaceutical
marketing. Today, she continues to define herself as a marketing strategist who is now able to apply her passion for marketing
strategy to a broader set of products and coach a larger team in this area.
Since she began her career in 1995, Sablich admits that more has changed in pharma than has remained constant. However, she
would advocate that the basics of solid marketing strategy still hold. "Now more than ever, it is critical to develop solid
insights about our market dynamics, customer needs, and competitors, and to prioritize customer segments, and develop an offering
that meets or exceeds customer expectations," says Sablich, who believes that to prevail and succeed in a new era of competitive
scarcity, one must remember that strategy development also requires an equal complement of strong execution, exemplified by
the removal of barriers to efficient decision-making—one of which is having fewer layers of management.
Associate Director, CMC Team Leader, Portfolio Management & Technical Integration, Johnson & Johnson
"What appeals to me most about the pharmaceutical industry is our focus on the development of new medicines to improve patients'
lives," says Denny Kraichely, Johnson & Johnson's associate director and CMC team leader in portfolio management and technical
integration. "It inspires me that I am a part of a pharmaceutical industry with so many examples of changing life-threatening
diseases to manageable chronic conditions."
At J&J, Kraichely is tasked with leading multiple CMC teams spanning from pre-new molecular entity (NME) declaration through
post-approval. He serves as single point-of-contact for all aspects of chemistry, manufacturing, and controls for several
compound development teams and supports the objectives of his company's strategy to engage in multiple therapeutic areas.
When he isn't reviewing manuscripts for scientific journals and trade publications, Kraichely is helping to develop programs
from scientific conferences. "I strongly feel that sharing knowledge is a key enabler that will allow our industry to continue
to bring life-changing medicines to the patients we serve."
Another guiding principle for Kraichely is that a lean organization depends heavily on communication, pushing boundaries,
and challenging the status quo while maintaining a strong sense of confidence and self-awareness. "The pharmaceutical industry
is perfectly positioned and equipped with unprecedented technical knowledge to meet the needs of patients around the world,"
adds Kraichely. "As an industry, we need to continue to play an active role to ensure that payer reimbursement challenges
do not prevent patient access to our life-changing medicines." Fighting that battle internally to ensure good science prevails
is just as important as dealing with outside vendors.